NL-OMON29757Not yet recruitingNot Applicable
Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases - Avastin-scanning in patients with colorectal liver metastases
niversitair Medisch Centrum Sint Radboud0 sites10 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Colorectal liver metastases, planned surgical resection within 6 weeks.
Exclusion Criteria
- •Pregnancy, lactation, recent chemotherapy (within 3 months after last chemotherapy regimen).
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma; a feasibility study in patients who do not show response on bevacizumab therapy.10017990colon cancerNL-OMON31048niversitair Medisch Centrum Groningen6
Completed
Not Applicable
Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma. A feasibility study in patients who do show response on bevacizumab therapy10017990colon cancerNL-OMON30912niversitair Medisch Centrum Groningen6
Active, not recruiting
Not Applicable
Evaluation of protein expression with labeled-bevacizumab scan in patients with relapsing multiple myeloma.EUCTR2012-002335-28-NLniversity medical centre groningen20
Completed
Not Applicable
Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study.Multiple myeloma AND Kahler's disease1003522710005959NL-OMON37271niversitair Medisch Centrum Groningen20
Completed
Not Applicable
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26